Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma

Jiménez-Ramírez, Carmina; Casjens, Swaantje; Juárez-Pérez, Cuauhtémoc Arturo; Raiko, Irina; Razo, Luz María Del; Taeger, Dirk; Calderón-Aranda, Emma S.; Rihs, Hans‐Peter; Acosta‐Saavedra, Leonor C.; Weber, Daniel G.; Cabello-López, Alejandro; Pesch, Beate; Ochoa-Vázquez, María Dolores; Burek, Katarzyna; Torre-Bouscoulet, Luis; Pérez-Padilla, José Rogelio; García-Bazan, Erik Marco; Brüning, Thomas; Johnen, Georg; Aguilar-Madrid, Guadalupe

doi:10.1007/s00408-019-00244-1

Cited by 19 publications

(29 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher calretinin concentrations were observed in the six women in comparison to the 56 men. Based on the small number of female participants in the study group, random results could not be excluded, but similar gender-based differences were already observed [10,11]. Higher calretinin serum levels in women might be based on the expression of calretinin in ovarian tissue [16].…”

Section: Discussionmentioning

confidence: 97%

“…A meta-analysis proves the benefit of calretinin determination in pleural effusion for the differentiation of malignant mesotheliomas from other malignancies [8]. Additionally, calretinin might be useful as circulating marker in plasma [9][10][11][12]. It is indicated that calretinin might be applicable as marker in field studies, because plasma calretinin is stable regarding repeated freeze/thaw cycles and storage at suboptimal temperatures [9].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Determinants of plasma calretinin in patients with malignant pleural mesothelioma

et al. 2020

Self Cite

View full text Add to dashboard Cite

Objective: Calretinin is a well-known immunohistochemical tissue marker in the diagnosis of malignant mesothelioma. Promising results also indicate the use in early detection. In the present cross-sectional survey, correlations of calretinin plasma levels with clinical features were investigated. Plasma samples of 60 patients with malignant pleural mesothelioma (MPM) and 111 cancer-free controls formerly exposed to asbestos were compared. Calretinin concentrations were determined in plasma using an enzyme-linked immunosorbent assay (ELISA). Results: The median concentration was higher in MPM patients than in controls (0.79 vs. 0.23 ng/ml; p < 0.0001). Patients with epithelioid MPM or biphasic MPM had higher calretinin plasma levels than patients with sarcomatoid MPM. Strong expression of calretinin in the tumor tissue was associated with higher plasma levels. Preoperative patients showed higher levels of calretinin than patients after thoracic surgery (1.20 vs. 0.67 ng/ml; p = 0.096). The suitability of plasma calretinin has been confirmed as a tumor marker in the differential diagnosis of epithelioid MPM. The value of plasma calretinin for therapy monitoring or as a prognostic marker should be further investigated.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

Determinants of plasma calretinin in patients with malignant pleural mesothelioma

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Among the positive immunohistochemical MM markers that can discriminate between malignant and mesothelial cells with the highest sensitivity and specificity are calretinin, cytokeratin5/6, and WT1 [76]. As biomarkers that would enable an earlier noninvasive diagnosis of MM are widely studied, recent studies evaluated if soluble calretinin could also be used as a biomarker in MM [75,[77][78][79][80].…”

Section: Calretininmentioning

confidence: 99%

“…In a recent study that evaluated soluble mesothelin, calretinin, and megakaryocyte potentiating factor, the use of composite of these biomarkers improved the performance for diagnosis of pleural MM compared to population controls [78]. The combination of calretinin and megakaryocyte potentiating factor had the highest sensitivity in men, while the combination of calretinin and mesothelin had the highest sensitivity in women [78].…”

Section: The Role Of Composite Blood Biomarkers In Asbestos-related Dmentioning

confidence: 99%

Asbestos-Related Diseases and Blood Biomarkers

Franko¹,

Dolžan²,

Goričar³

et al. 2020

Asbestos-Related Diseases

View full text Add to dashboard Cite

Asbestos-related diseases, including asbestosis, benign pleural diseases, lung cancer, other types of cancer, and especially malignant mesothelioma (MM), still represent an enormous problem all over the world and are among the most investigated occupational diseases. Considering that MM is a highly aggressive and severe malignant cancer of pleura, peritoneum and other serosal surfaces, new blood biomarkers for earlier diagnosis, following response to treatment and disease progression, have been intensively investigated. Several studies suggested that soluble mesothelin-related peptides, fibulin-3, survivin, osteopontin, vimentin, calretinin, and many others could be helpful in diagnosis, detecting the progression of MM and evaluating tumour response to treatment; however, these biomarkers have not been validated in clinical practice. Therefore, search for novel better stand-alone or composite biomarkers is under way. The aim of this chapter is to present the importance of blood biomarkers in evaluating the risk of developing asbestos-related diseases, early diagnosis, following the response to treatment and progression of these diseases, with special emphasis on MM.

show abstract

“…In a meta-analysis, the overall sensitivity and specificity of osteopontin in MPM diagnosis were found 0.65 (95% CI: 0.60-0.70) and 0.81 (95% CI: 0.78-0.85), respectively [27]. Some recent studies have shown that the combined use of these potential biomarkers in asbestos exposed population may improve the accuracy of the diagnostic performance of individual markers [28][29][30][31].…”

Section: Introductionmentioning

confidence: 99%

Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review

Töreyin

Ghosh

Göksel

et al. 2020

IJERPH

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is mainly related to previous asbestos exposure. There is still dearth of information on non-invasive biomarkers to detect MPM at early stages. Human studies on exhaled breath biomarkers of cancer and asbestos-related diseases show encouraging results. The aim of this systematic review was to provide an overview on the current knowledge about exhaled breath analysis in MPM diagnosis. A systematic review was conducted on MEDLINE (PubMed), EMBASE and Web of Science databases to identify relevant studies. Quality assessment was done by the Newcastle–Ottawa Scale. Six studies were identified, all of which showed fair quality and explored volatile organic compounds (VOC) based breath profile using Gas Chromatography Coupled to Mass Spectrometry (GC–MS), Ion Mobility Spectrometry Coupled to Multi-capillary Columns (IMS–MCC) or pattern-recognition technologies. Sample sizes varied between 39 and 330. Some compounds (i.e, cyclohexane, P3, P5, P50, P71, diethyl ether, limonene, nonanal, VOC IK 1287) that can be indicative of MPM development in asbestos exposed population were identified with high diagnostic accuracy rates. E-nose studies reported breathprints being able to distinguish MPM from asbestos exposed individuals with high sensitivity and a negative predictive value. Small sample sizes and methodological diversities among studies limit the translation of results into clinical practice. More prospective studies with standardized methodologies should be conducted on larger populations.

show abstract

Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma

Cited by 19 publications

References 28 publications

Determinants of plasma calretinin in patients with malignant pleural mesothelioma

Determinants of plasma calretinin in patients with malignant pleural mesothelioma

Asbestos-Related Diseases and Blood Biomarkers

Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review

Contact Info

Product

Resources

About